{"id":103603,"date":"2025-07-30T02:05:12","date_gmt":"2025-07-30T02:05:12","guid":{"rendered":"https:\/\/www.europesays.com\/us\/103603\/"},"modified":"2025-07-30T02:05:12","modified_gmt":"2025-07-30T02:05:12","slug":"vinay-prasad-departs-fda-stat","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/103603\/","title":{"rendered":"Vinay Prasad departs FDA | STAT"},"content":{"rendered":"<p class=\"author-bio\">Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast <a href=\"https:\/\/www.statnews.com\/category\/readout-loud\/\" target=\"_blank\" rel=\"noopener\">The Readout Loud<\/a> and author of the newsletter <a href=\"https:\/\/www.statnews.com\/signup\/scorecard\/\" target=\"_blank\" rel=\"noopener\">Adam\u2019s Biotech Scorecard.<\/a> You can reach Adam on Signal at stataf.54.<\/p>\n<p>Vinay Prasad, a top official at the Food and Drug Administration, has suddenly departed after a series of controversial decisions about a <a href=\"https:\/\/www.statnews.com\/2025\/07\/28\/sarepta-duchenne-elevidys-hold-ambulatory\/\" target=\"_blank\" rel=\"noopener\">treatment for boys with Duchenne muscular dystrophy<\/a>.<\/p>\n<p>\u201cDr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family,\u201d Health and Human Services Department spokesperson Andrew Nixon told STAT. \u201cWe thank him for his service and the many important reforms he was able to achieve in his time at FDA.\u201d<\/p>\n<p>Prasad was the head of the Food and Drug Administration division that regulates vaccines, gene therapies, and blood products. He was also the <a href=\"https:\/\/www.statnews.com\/2025\/06\/18\/vinay-prasad-fda-cber-chief-medical-science-officer-advise-makary\/\" target=\"_blank\" rel=\"noopener\">agency\u2019s chief medical and scientific officer<\/a>, making him a top adviser to Commissioner Marty Makary. Prasad didn\u2019t immediately respond to requests for comment.<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" target=\"_blank\" rel=\"noopener\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/06\/stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" target=\"_blank\" rel=\"noopener\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus daily intelligence on Capitol Hill and the life sciences industry \u2014 by subscribing to STAT+.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" target=\"_blank\" rel=\"noopener\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" target=\"_blank\" rel=\"noopener\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" target=\"_blank\" rel=\"noopener\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall&hellip;\n","protected":false},"author":3,"featured_media":103604,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[150,64,151,152,153,154,67,132,68],"class_list":{"0":"post-103603","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business","8":"tag-biotechnology","9":"tag-business","10":"tag-fda","11":"tag-pharmaceuticals","12":"tag-policy","13":"tag-stat","14":"tag-united-states","15":"tag-unitedstates","16":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114939740083437662","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/103603","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=103603"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/103603\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/103604"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=103603"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=103603"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=103603"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}